KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Inclusion Criteria

• •1. Being voluntary to sign the informed consent form.
• •2. Male or female, aged ≥ 18 years.
• •3. Patients whose estimated survival time is more than 3 months.
• •4. Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1.
• •5. Histologically or cytologically confirmed advanced or metastatic melanoma, and the overall proportion of subjects with mucosal malignant melanoma will not exceed 22%.
• •6. At least one measurable lesion is used as the target lesion according to the Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST V1.1).
• •7. The results of laboratory examination during the screening period suggest that the subjects have good organ function.
• •8. Male subjects with reproductive ability or female subjects with the possibility of pregnancy use effective contraceptive methods.
• •9. Good compliance and follow-up.